PROCEPT BioRobotics® Hosts 2026 Investor Day to Detail Multi-year Financial Outlook and Strategic Plan for Long-Term Growth

Core Insights - PROCEPT BioRobotics Corporation hosted its 2026 Investor Day to discuss market opportunities, long-term strategy, growth goals, and financial guidance for 2026-2027 [1] Market Opportunity - The company highlighted a significant underpenetrated market in Benign Prostatic Hyperplasia (BPH), with 40 million men in the U.S. affected [2][5] - PROCEPT has treated over 125,000 patients, showcasing a strong foundation of technology and clinical evidence [2][5] Strategic Focus - The CEO emphasized a shift towards establishing leadership in BPH through a comprehensive solution that provides durable symptom relief and lower adverse outcomes [3] - Future strategies will include growth in Aquablation procedures, disciplined pricing, commercial execution, patient education, and international expansion [3] Financial Guidance - The company projects annual revenue growth of 27% to 33% for 2026, with procedure growth expected to be between 39% and 48% [9] - For 2027, annual revenue growth is anticipated to be 25% to 30% [9] - Gross margins are expected to improve to 65% in 2026 and 68% to 70% in 2027 [9] - Positive adjusted EBITDA is expected in Q4 2026, with a gain of $25 to $30 million projected for 2027 [9]